Stay updated with breaking news from Practice Patterns Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CKD-aP patients receiving maintenance hemodialysis reported adverse clinical events in line with their pruritus severity and were found to be at greater risk of all-cause mortality, all-cause hospitalization, and cardiovascular events.
Investigators assessed the benefits of cinacalcet (approved in 2004) vs etelcalcetide (approved in 2017) for patients on hemodialysis.
The 2019 landmark PIVOTAL trial that established the safety and efficacy of higher-dose iron in patients on hemodialysis had little discernable impact on US practice, which already used higher doses.
Recent study findings could explain the preponderance of men in the dialysis population.
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno,...